摘要
目的：探讨DMBT1基因纯合性缺失与乳腺癌临床病理特征的关系。方法采用聚合酶链反应检测乳腺癌DMBT1基因纯合性缺失，分析其与乳腺癌临床病理特征的关系。结果60例乳腺癌组织标本中27例有DMBT1基因纯合性缺失，缺失率为45％。浸润性乳腺癌患者的DMBT1基因纯合性缺失率高于非浸润性乳腺癌患者，伴有淋巴和（或）远处转移的患者DMBT1基因纯合性缺失率高于不伴转移的患者，Ⅰ期患者低于Ⅱ∽Ⅲ期患者，差异均有统计学意义（P＜0．05）。结论DMBT1基因与乳腺癌的临床病理特征有密切关系，提示DMBT1的纯合性缺失可能与乳腺癌的病例特征、转移及转化有关，同时对于乳腺癌的诊断、治疗和预后具有重要的临床意义。
Objective To study the relationship between homozygous deletions of DMBT1 gene and clinicopathology character-istics of breast cancer.Methods Homozygous deletions of DMBT1 gene were detected by polymerase chain reaction in 60 patients with breast tumors.Results Among the 60 patients,27 cases were found with intragenic homozygous deletions of DMBT1 ,and the ratio of homozygous deletions was 45%.The ratio of intragenic homozygous deletions of DMBT1 in patients with invasive breast cancer was significantly higher than patients with noninvasive breast cancer （P〈0.05）.The deletions occurred significantly more often in patients with lymphoid or/and metastasis （P〈0.05）.Deletions rate in patients at Ⅰ stage were significantly lower than patients at Ⅱ-Ⅲ stage （P〈0.05）.Conclusion DMBT1 gene could be closely correlated with clinicopathology characteristics of breast cancer.Homozygous deletions of the DMBT1 gene might be associated with clinicopathology characteristics,metastasis and transformation of breast cancer,which could be with important clinical significance for diagnosis,treatment and prognosis judgment of breast cancer.
出处
《国际检验医学杂志》
CAS
2014年第12期1550-1551,1554,共3页
International Journal of Laboratory Medicine
基金
济宁市科技局基金资助项目(2012jnjc14)
